[go: up one dir, main page]

AR090056A1 - Anticuerpos anti-cxcr3 - Google Patents

Anticuerpos anti-cxcr3

Info

Publication number
AR090056A1
AR090056A1 ARP130100184A ARP130100184A AR090056A1 AR 090056 A1 AR090056 A1 AR 090056A1 AR P130100184 A ARP130100184 A AR P130100184A AR P130100184 A ARP130100184 A AR P130100184A AR 090056 A1 AR090056 A1 AR 090056A1
Authority
AR
Argentina
Prior art keywords
cxcr3
antibodies
cxcr3 antibodies
diagnose
antibody
Prior art date
Application number
ARP130100184A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR090056A1 publication Critical patent/AR090056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Anticuerpos anti CXCR3 (Receptor 3 de quimiocina) y métodos para usar los anticuerpos para diagnosticar y/o tratar los trastornos asociados con CXCR3 tales como diabetes mellitas tipo I (T1D), particularmente T1D de reciente comienzo. En ciertas formas de realización, se describen anticuerpos neutralizantes de CXCR3. Ácido nucleico, vector, célula huésped, método para producir el anticuerpo y composición farmacéutica.
ARP130100184A 2012-01-20 2013-01-21 Anticuerpos anti-cxcr3 AR090056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20

Publications (1)

Publication Number Publication Date
AR090056A1 true AR090056A1 (es) 2014-10-15

Family

ID=47633576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100184A AR090056A1 (es) 2012-01-20 2013-01-21 Anticuerpos anti-cxcr3

Country Status (27)

Country Link
US (4) US8865870B2 (es)
EP (1) EP2804878B1 (es)
JP (3) JP6352812B6 (es)
KR (2) KR20200014441A (es)
CN (1) CN104507967B (es)
AR (1) AR090056A1 (es)
AU (1) AU2013209492B2 (es)
BR (1) BR112014017814A8 (es)
CA (1) CA2862222A1 (es)
CY (1) CY1121335T1 (es)
DK (1) DK2804878T3 (es)
ES (1) ES2698606T3 (es)
HK (1) HK1208684A1 (es)
HR (1) HRP20181874T1 (es)
HU (1) HUE041900T2 (es)
IL (2) IL233694A0 (es)
LT (1) LT2804878T (es)
MX (1) MX359854B (es)
PL (1) PL2804878T3 (es)
PT (1) PT2804878T (es)
RS (1) RS58141B1 (es)
RU (1) RU2663141C2 (es)
SG (2) SG10201700735PA (es)
SI (1) SI2804878T1 (es)
TW (1) TWI596112B (es)
UY (1) UY34582A (es)
WO (1) WO2013109974A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
BR112017003487A2 (pt) * 2014-08-22 2017-11-28 Sorrento Therapeutics Inc ?anticorpo totalmente humano, fragmento de fab de anticorpo totalmente humano, anticorpo humano de fita simples, anticorpo de fita simples totalmente humano, método de tratamento de amplo espectro de cânceres e método de tratamento de distúrbios inflamatórios?
AU2016343987B2 (en) * 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
WO2017205377A2 (en) * 2016-05-23 2017-11-30 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
TW201840585A (zh) 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
KR20190095942A (ko) * 2016-12-22 2019-08-16 사노피 백반증의 치료를 위한 항-인간 cxcr3 항체
CA3091311A1 (en) * 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
EP4245373A3 (en) 2020-02-26 2023-12-20 VIR Biotechnology, Inc. Antibodies against sars-cov-2
CN116234572A (zh) * 2020-04-30 2023-06-06 安驰肿瘤公司 治疗性SIRPα抗体
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022187275A1 (en) * 2021-03-02 2022-09-09 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2024052445A1 (en) 2022-09-09 2024-03-14 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3590766C2 (es) 1985-03-30 1991-01-10 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5766886A (en) 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE360689T1 (de) * 1996-09-10 2007-05-15 Kocher Theodor Inst Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
CA2536644A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
EP1631315B1 (en) * 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
EA014112B1 (ru) * 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
MX2007001638A (es) 2004-08-11 2009-02-12 Trubion Pharmaceuticals Inc Proteinas de fusion del dominio de unión.
MX2008013057A (es) 2006-04-14 2009-04-07 Trubion Pharmaceuticals Inc Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
WO2008094942A2 (en) 2007-02-01 2008-08-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against cxcr3
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
WO2010056907A2 (en) 2008-11-12 2010-05-20 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) * 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

Also Published As

Publication number Publication date
PT2804878T (pt) 2018-11-29
PL2804878T3 (pl) 2019-03-29
CN104507967B (zh) 2018-10-12
US20190119391A1 (en) 2019-04-25
LT2804878T (lt) 2018-12-10
IL233694A0 (en) 2014-09-30
EP2804878B1 (en) 2018-08-22
WO2013109974A3 (en) 2013-11-07
CY1121335T1 (el) 2020-05-29
US8865870B2 (en) 2014-10-21
KR20200014441A (ko) 2020-02-10
RU2014134043A (ru) 2016-03-20
JP6646100B2 (ja) 2020-02-14
KR102073034B1 (ko) 2020-02-05
JP2015506945A (ja) 2015-03-05
SG10201700735PA (en) 2017-02-27
JP6352812B2 (ja) 2018-07-04
AU2013209492B2 (en) 2018-02-08
TW201335188A (zh) 2013-09-01
JP6352812B6 (ja) 2018-08-08
WO2013109974A2 (en) 2013-07-25
RS58141B1 (sr) 2019-02-28
HRP20181874T1 (hr) 2019-01-11
BR112014017814A2 (es) 2017-06-20
EP2804878A2 (en) 2014-11-26
US20130251733A1 (en) 2013-09-26
US20180086838A1 (en) 2018-03-29
UY34582A (es) 2013-09-02
HK1208684A1 (en) 2016-03-11
BR112014017814A8 (pt) 2017-07-11
MX2014008728A (es) 2015-07-06
US9765144B2 (en) 2017-09-19
TWI596112B (zh) 2017-08-21
JP2020072715A (ja) 2020-05-14
HUE041900T2 (hu) 2019-06-28
RU2663141C2 (ru) 2018-08-01
JP2018166506A (ja) 2018-11-01
IL271697A (en) 2020-02-27
ES2698606T3 (es) 2019-02-05
KR20140116525A (ko) 2014-10-02
US20140377806A1 (en) 2014-12-25
MX359854B (es) 2018-10-12
AU2013209492A1 (en) 2014-08-14
CN104507967A (zh) 2015-04-08
CA2862222A1 (en) 2013-07-25
SI2804878T1 (sl) 2018-12-31
SG11201406762QA (en) 2014-11-27
DK2804878T3 (en) 2018-12-17

Similar Documents

Publication Publication Date Title
AR090056A1 (es) Anticuerpos anti-cxcr3
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MX375911B (es) Constructos de anticuerpo multiespecifico.
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
AR088941A1 (es) Anticuerpos anti-fgfr2 y sus usos
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
MX2015012862A (es) Moleculas de union para bcma y cd3.
ECSP14004829A (es) Moléculas de unión para bcma y cd3
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
PE20190229A1 (es) Anticuerpos anti-fcrn
BR112015019603A2 (pt) Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
AR089178A1 (es) Anticuerpos anti-il-36r
CR20190431A (es) Formatos mejorados de receptor de unión a antígeno
UY32917A (es) Moléculas de unión a dll-4
UY33588A (es) Moleculas de union a vegf
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car

Legal Events

Date Code Title Description
FB Suspension of granting procedure